Aqua Medical Builds an Endoscopic Therapy for Diabetes

Aqua Medical is building a minimally invasive endoscopic platform for a problem medicine has mostly managed with drugs, injections, and surgery: type 2 diabetes. The Pleasanton, California company is developing Proximal Intestinal Mucosal Ablation, or PIMA, an investigational procedure designed to treat targeted tissue in the upper small intestine with radiofrequency-generated water vapor.

The pitch is ambitious, but the mechanism is refreshingly concrete. A physician passes Aqua Medical's catheter through the working channel of a standard endoscope, delivers controlled vapor to the mucosal layer, and avoids external incisions or permanent changes to gastrointestinal anatomy. The company is now moving from early international evidence into broader U.S. clinical evaluation.

That transition matters more than any funding headline. Aqua Medical's latest Series B gives the company capital to complete its U.S. RESTORE-1 pilot and prepare for a planned pivotal study. The next chapter is not about proving that vapor can reach the tissue. It is about proving that the procedure can produce a durable metabolic benefit with an acceptable safety profile in a larger, more rigorous trial.

What Aqua Medical is building

Aqua Medical's radiofrequency vapor ablation platform uses a generator to create heated water vapor and proprietary catheters to deliver it through an endoscope. The platform is designed for diseases throughout the gastrointestinal tract, with potential applications spanning Barrett's esophagus, pancreatic cysts, and metabolic disease.

PIMA is the company's lead metabolic program. It targets the mucosa of the duodenum and proximal jejunum, regions increasingly studied for their role in insulin resistance, nutrient signaling, and glucose regulation. The concept is to resurface targeted tissue without rerouting the digestive tract, turning a familiar GI procedure into a potential metabolic intervention.

The workflow is part of the product strategy. Aqua Medical says its catheter fits through a standard endoscope, does not require fluoroscopy, and is being designed with outpatient and ambulatory surgery center delivery in mind. If clinical evidence holds up, that familiarity could reduce the operational friction that often traps promising medical technology between a successful trial and actual adoption.

The regulatory line matters

Aqua Medical's RFVA system received FDA 510(k) clearance under K241271 for its indicated gastrointestinal coagulation and ablation use. That is not the same as clearance or approval to treat diabetes.

PIMA remains investigational for type 2 diabetes. It is not commercially available for that indication, and its safety and effectiveness have not been established. That distinction is easy to lose in a category where a cleared device platform, a novel procedure, and an active clinical trial can sound like one completed regulatory event. They are not.

The current U.S. program, RESTORE-1, is a pilot study evaluating safety, tolerability, and effectiveness in adults with inadequately controlled type 2 diabetes. Aqua Medical reported the first U.S. patient treated at UNC Health in July 2026 after more than 66 patients had been treated in international development. The international patient count is company-reported.

What the early evidence says

The most useful evidence so far is a peer-reviewed first-in-human pilot. The prospective study enrolled 27 patients, with 25 receiving the treatment dose. Investigators reported technical success in all procedures, no serious adverse events, and preliminary reductions in HbA1c.

Those findings are encouraging, not conclusive. The trial was open-label, nonrandomized, single-center, uncontrolled, and too small to establish efficacy. The authors explicitly called for larger studies. That is the correct frame for Aqua Medical today: a credible clinical signal entering the part of medtech development where controls, durability, site-to-site repeatability, and regulatory discipline do the talking.

The opportunity is still substantial. Type 2 diabetes affects millions of Americans, and many patients struggle to reach durable glycemic targets despite a crowded medication market. An outpatient procedure that meaningfully improves metabolic control without surgery would create a new lane between chronic pharmacotherapy and anatomy-altering intervention. The word doing the heavy lifting is “would.”

Leadership built around GI commercialization

Aqua Medical is led by Robert “Bob” Haggerty, who became president and CEO in July 2026 after more than 35 years in medical devices and more than 30 years in gastroenterology. At BÂRRX Medical, Haggerty helped commercialize radiofrequency ablation for Barrett's esophagus before Covidien acquired the company. That background fits Aqua Medical's current challenge: translating an energy-based GI technology from clinical promise into a repeatable market.

Founder Virender K. Sharma, MD, serves as chief medical officer and director. Aqua Medical credits Sharma with more than 300 peer-reviewed articles and presentations and extensive work across gastroenterology, endoscopy, and early-stage device development. The broader leadership team includes CFO Greg Wilson, vice president of R&D Scott McGill, chief medical officer Raj Nihalani, and clinical research manager Alina Stoica.

Public company records date Aqua Medical to 2016, although the current official site does not state a founding year. LinkedIn lists the company as a privately held medical-equipment manufacturer with 11 to 50 employees. No official careers page or current open-role list was verified, so growth should be read through its clinical, regulatory, and leadership milestones rather than an unsupported hiring narrative.

Financing the proof, not the promise

Aqua Medical completed a $15.5 million Series A in 2020. In September 2026, Relevance Ventures led a new multimillion-dollar Series B. The company did not disclose the exact amount, other participating investors, valuation, or total capital raised.

The stated use of proceeds is unusually specific: complete RESTORE-1 and prepare for a planned pivotal trial, subject to regulatory authorization. That is where the company's value can change quickly in either direction. A successful U.S. pilot would strengthen the case for a pivotal program and help define procedure training, patient selection, and trial endpoints. A weak or ambiguous signal would expose how much of the thesis still depends on biology that has not been settled.

Aqua Medical sits at the intersection of gastroenterology, metabolic care, and medical-device commercialization. The company is not selling a diabetes procedure today. It is trying to establish whether a familiar endoscopic workflow can become a new therapeutic category. The Series B buys more runway, but the evidence will decide whether endoscopic metabolic restoration becomes a clinical discipline or remains an elegant hypothesis.